Canada’s Drug Agency has received a letter from The Honourable Mark Holland that outlines our time-limited work related to An Act respecting pharmacare, which received royal assent on October 10, 2024.
Canada’s Drug Agency is proud to welcome Maureen Smith as the first-ever Patient Member on our Board of Directors. Maureen is a respected leader in the field of patient engagement, and she brings a unique perspective to our table, grounded in lived and living experience.
A new coalition, announced today, unites 11 organizations that are working collectively to improve the appropriate prescribing and use of medications in Canada.
Initially formed in 2023, the Appropriate Use Coalition is a grassroots group comprised of health care organizations and public representation that is committed to improving patient outcomes and reducing risks through appropriate prescribing.
Current consultation status: Closed
Consultation period: November 28 to January 28, 2025
Canada’s Drug Agency is launching a consultation on our first-ever methods guide. The development of the guide and our open consultation are both part of our ambition to increase the transparency of our processes and provide a better understanding of our work.